These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 26354796)

  • 1. Boronic prodrug of 4-hydroxytamoxifen is more efficacious than tamoxifen with enhanced bioavailability independent of CYP2D6 status.
    Zhong Q; Zhang C; Zhang Q; Miele L; Zheng S; Wang G
    BMC Cancer; 2015 Sep; 15():625. PubMed ID: 26354796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Boronic prodrug of endoxifen as an effective hormone therapy for breast cancer.
    Zhang C; Zhong Q; Zhang Q; Zheng S; Miele L; Wang G
    Breast Cancer Res Treat; 2015 Jul; 152(2):283-91. PubMed ID: 26071758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endoxifen, a new cornerstone of breast cancer therapy: demonstration of safety, tolerability, and systemic bioavailability in healthy human subjects.
    Ahmad A; Shahabuddin S; Sheikh S; Kale P; Krishnappa M; Rane RC; Ahmad I
    Clin Pharmacol Ther; 2010 Dec; 88(6):814-7. PubMed ID: 20981001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Orally administered endoxifen is a new therapeutic agent for breast cancer.
    Ahmad A; Ali SM; Ahmad MU; Sheikh S; Ahmad I
    Breast Cancer Res Treat; 2010 Jul; 122(2):579-84. PubMed ID: 20052538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate.
    Marathe PH; Kamath AV; Zhang Y; D'Arienzo C; Bhide R; Fargnoli J
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):55-66. PubMed ID: 19396600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant percutaneous 4-hydroxytamoxifen decreases breast tumoral cell proliferation: a prospective controlled randomized study comparing three doses of 4-hydroxytamoxifen gel to oral tamoxifen.
    Rouanet P; Linares-Cruz G; Dravet F; Poujol S; Gourgou S; Simony-Lafontaine J; Grenier J; Kramar A; Girault J; Le Nestour E; Maudelonde T
    J Clin Oncol; 2005 May; 23(13):2980-7. PubMed ID: 15860853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose-adjustment study of tamoxifen based on CYP2D6 genotypes in Japanese breast cancer patients.
    Kiyotani K; Mushiroda T; Imamura CK; Tanigawara Y; Hosono N; Kubo M; Sasa M; Nakamura Y; Zembutsu H
    Breast Cancer Res Treat; 2012 Jan; 131(1):137-45. PubMed ID: 21947681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endoxifen levels and its association with CYP2D6 genotype and phenotype: evaluation of a southern Brazilian population under tamoxifen pharmacotherapy.
    Antunes MV; Linden R; Santos TV; Wallemacq P; Haufroid V; Classen JF; Andreolla H; Costa N; Fontanive TO; Rosa DD
    Ther Drug Monit; 2012 Aug; 34(4):422-31. PubMed ID: 22777153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Formulation of Anti-miR-21 and 4-Hydroxytamoxifen Co-loaded Biodegradable Polymer Nanoparticles and Their Antiproliferative Effect on Breast Cancer Cells.
    Devulapally R; Sekar TV; Paulmurugan R
    Mol Pharm; 2015 Jun; 12(6):2080-92. PubMed ID: 25880495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized phase II presurgical trial of transdermal 4-hydroxytamoxifen gel versus oral tamoxifen in women with ductal carcinoma in situ of the breast.
    Lee O; Page K; Ivancic D; Helenowski I; Parini V; Sullivan ME; Margenthaler JA; Chatterton RT; Jovanovic B; Dunn BK; Heckman-Stoddard BM; Foster K; Muzzio M; Shklovskaya J; Skripkauskas S; Kulesza P; Green D; Hansen NM; Bethke KP; Jeruss JS; Bergan R; Khan SA
    Clin Cancer Res; 2014 Jul; 20(14):3672-82. PubMed ID: 25028506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of curcumin on the pharmacokinetics of tamoxifen and its active metabolite, 4-hydroxytamoxifen, in rats: possible role of CYP3A4 and P-glycoprotein inhibition by curcumin.
    Cho YA; Lee W; Choi JS
    Pharmazie; 2012 Feb; 67(2):124-30. PubMed ID: 22512082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of clinically therapeutic endoxifen concentrations based on efficacy from human MCF7 breast cancer xenografts.
    Gong IY; Teft WA; Ly J; Chen YH; Alicke B; Kim RB; Choo EF
    Breast Cancer Res Treat; 2013 May; 139(1):61-9. PubMed ID: 23605084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft.
    Luo FR; Yang Z; Dong H; Camuso A; McGlinchey K; Fager K; Flefleh C; Kan D; Inigo I; Castaneda S; Rose WC; Kramer RA; Wild R; Lee FY
    Cancer Chemother Pharmacol; 2005 Nov; 56(5):455-64. PubMed ID: 15947929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users.
    Bijl MJ; van Schaik RH; Lammers LA; Hofman A; Vulto AG; van Gelder T; Stricker BH; Visser LE
    Breast Cancer Res Treat; 2009 Nov; 118(1):125-30. PubMed ID: 19189212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of morin on the bioavailability of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats.
    Shin SC; Piao YJ; Choi JS
    In Vivo; 2008; 22(3):391-5. PubMed ID: 18610753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel prodrug of the green tea polyphenol (-)-epigallocatechin-3-gallate as a potential anticancer agent.
    Landis-Piwowar KR; Huo C; Chen D; Milacic V; Shi G; Chan TH; Dou QP
    Cancer Res; 2007 May; 67(9):4303-10. PubMed ID: 17483343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of epigallocatechin gallate on the oral bioavailability and pharmacokinetics of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats.
    Shin SC; Choi JS
    Anticancer Drugs; 2009 Aug; 20(7):584-8. PubMed ID: 19491656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of CYP2D6 polymorphisms and tamoxifen in women with breast cancer.
    Gaston C; Kolesar J
    Clin Adv Hematol Oncol; 2008 Nov; 6(11):825-33. PubMed ID: 19194367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice.
    Ruddy KJ; Desantis SD; Gelman RS; Wu AH; Punglia RS; Mayer EL; Tolaney SM; Winer EP; Partridge AH; Burstein HJ
    Breast Cancer Res Treat; 2013 Oct; 141(3):421-7. PubMed ID: 24062210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced bioavailability of tamoxifen and its metabolite 4-hydroxytamoxifen after oral administration with biochanin A (an isoflavone) in rats.
    Singh SP; Wahajuddin ; Raju KS; Ali MM; Kohli K; Jain GK
    Phytother Res; 2012 Feb; 26(2):303-7. PubMed ID: 22131128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.